🇺🇸 FDA
Patent

US 11422132

Peptides and uses thereof for diagnosing and treating myasthenia gravis

granted A61KA61K38/00A61K47/6849

Quick answer

US patent 11422132 (Peptides and uses thereof for diagnosing and treating myasthenia gravis) held by The Regents of the University of California expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K38/00, A61K47/6849, A61P, A61P21/04